Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013675
Chunk: 12

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 12
---
 million) resulted from the payment of deferred consideration
on the eRapa licence of £0.37 million (1H24: £0.85 million) offset by £0.04 million of interest received (1H24: £0.10
million).

Net cash generated
from financing activities in 1H25 was £6.01 million (1H24: inflow £4.65 million), which was driven by £6.20 million
proceeds from share issuances under the ELOC, £0.05 million net proceeds from a warrant inducement, offset by loan repayments (including
interest) of £0.15 million and payments on lease liabilities of £0.10 million.

Overall, cash increased
by £2.37 million in 1H25 compared to a decrease of £0.92 million in 1H24. This resulted in a cash balance at June 30, 2025
of £4.04 million compared with £5.05 million at June 30, 2024 and £1.67 million at December 31, 2024.

Going concern

Biodexa has experienced
net losses and significant cash outflows from cash used in operating activities over the past years as it develops its portfolio. For
the six months to June 30, 2025, the Group incurred a consolidated loss from operations of £3.81 million (1H24: £3.31 million)
and negative cash flows from operating activities of £3.30 million (1H24: £4.81 million). As of June 30, 2025, the Group had
accumulated deficit of £154.13 million.

The Group’s
future viability is dependent on its ability to raise cash from financing activities to finance its development plans until commercialisation,
generate cash from operating activities and to successfully obtain regulatory approval to allow marketing of its development products.
The Group’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue
its business strategies.

| 9 |

The Directors believe
there are adequate options and time available to secure additional financing for the Group and after considering the uncertainties, the
Directors consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements. The Group’s
consolidated financial statements have therefore been presented on a going concern basis, which contemplates the realisation of assets
and the satisfaction of liabilities in the